How do stem cells differentiate into cardiomyocytes?
Currently, cardiomyocytes can be differentiated from pluripotent stem cells by (1) spontaneous embryoid body (EB) differentiation in suspension, (2) coculture with mouse endoderm-like cells (END-2 cells), or (3) guiding the cardiac differentiation with defined growth factors either in suspension or in monolayer culture …
What can iPS cells differentiate into?
As pluripotent cells, iPS cells theoretically have the ability to generate all cell types found in the body. Human iPS cells have been differentiated into a variety of these, including adipocytes, cardiomyocytes, primitive hematopoietic cells, pancreatic beta-cells, and several different neuronal cell types.
What is the purpose of iPS cells?
iPSC are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes.
What are the differentiation of cardiomyocytes?
Current methods for PSC differentiation into cardiomyocytes can be divided into three categories: (i) differentiation via co-culture with mouse visceral endoderm-like (END-2) stromal cells, (ii) EB differentiation in suspension, and (iii) 2D monolayer differentiation.
What are iPSC derived cardiomyocytes?
Characteristics of iPSC-Cardiomyocytes iPSC-derived cardiomyocytes cultures include spontaneously beating cells and while immature in culture the cells co-express a mixture of atrial, ventricular and nodal markers – a diffferent expression profile to adult cardiomyocytes.
How do pluripotent stem cells differentiate?
Introduction. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are pluripotent stem cells (PSCs) that have two distinct features: the ability to proliferate in the undifferentiated state (self-renewal) and the potential to differentiate in response to differentiation stimuli.
What can induced pluripotent stem cells do?
Induced pluripotent stem cells (iPSCs) can self-renew indefinitely in culture and differentiate into all specialized cell types including gametes.
What are the differences between iPS cells and embryonic stem cells?
Embryonic stem (ES) cells are pluripotent stem cells derived from the inner cell mass of preimplantation embryos. Induced pluripotent stem (iPS) cells can be generated by somatic cell reprogramming following the exogenous expression of specific transcription factors (Oct-3/4, KLF4, SOX2, and c-Myc).
What are some advantages of iPS cells as compared to embryonic stem cells?
The primary advantages of iPSCs compared to other stem cells are: a) iPSCs can be created from the tissue of the same patient that will receive the transplantation, thus avoiding immune rejection, and b) the lack of ethical implications because cells are harvested from a willing adult without harming them.
How to differentiate iPSCs from iPSC to cardiomyocytes?
Now scientists at Creative Biolabs have developed three major approaches for differentiation of iPSCs to cardiomyocytes: Embryoid (EB), monolayer culture, and inductive coculture. Embryoid bodies (EBs) are three-dimensional aggregates which consist of cells from ectoderm, endoderm, and mesoderm.
How do hips cells differentiate into cardiomyocytes?
Gene expression studies demonstrated that the cardiomyocyte differentiation process of the hiPS cells was characterized by an initial increase in mesoderm and cardiomesoderm markers, followed by expression of cardiac-specific transcription factors and finally by cardiac-specific structural genes.
How are cardiomyocytes counted for cardiac differentiation?
Although early studies using EB-based differentiation protocols usually reported the percentage of contracting EBs as a measure for cardiac differentiation, more recent studies have described the proportion of cardiomyocytes, estimated by intracellular flow cytometry for a cardiac-specific protein such as cardiac troponin T.
Can human ESCs give rise to functional cardiomyocytes?
The demonstration that human ESCs can give rise to functional cardiomyocytes has promoted much discussion about the potential utility of hPSC-CMs. At the forefront of popular interest has been the promise of cardiomyocyte replacement therapies.